Asset Details
Do you wish to reserve the book?
The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab
Do you wish to request the book?
The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab
2013
Overview
In patients with rheumatoid arthritis (RA), the development of antibodies to infliximab (ATI) is associated with poor clinical response. 1 2-7 Nevertheless, there is no plausible explanation for why not all patients with ATI experience high disease activity. Table 1 Total: 11 patients with RA (%) Gender, female n (%) 11 (100) Age, mean (SD) 54.18±13.24 Autoantibodies: RF positive n (%) 9 (81.8) ACPA positive n (%) 9 (81.8) Disease duration (years), mean (SD) 14.20±6.42 Baseline DAS28, mean (SD) 5.45±1.13 Time under Ifx therapy in years, mean (SD) 8.00±2.75 ATI duration in years, mean (SD) 1.1±0.91 Concomitant treatment MTX alone 3 (27.2) OD 1 (9.0) MTX+OD 6 (54.8) Ifx monotherapy 1 (9.0) ACPA, Anticitrullinated protein antibody; ATI, antibodies to infliximab; DAS28, Disease Activity Score 28; Ifx, infliximab; MTX, Methotrexate; OD, Other DMARDs; RF, Rheumatoid Factor.
Publisher
BMJ Publishing Group Ltd and European League Against Rheumatism,Elsevier Limited
